Construction of our first major R&D and production facility in Wuxi, China has officially commenced. This marks a major milestone in our journey of becoming a fully vertically integrated and open MedTech platform; from R&D, manufacturing to direct product distribution and sales to hospitals and clinics.

Spanning approximately 140,000 sqm, the facility will enable us to independently R&D and manufacture innovations and products. A crucial necessity for us to streamline the way medical technology enters and scales for emerging markets throughout Asia-Pac, this is in line with our goal of disrupting the inefficiency and fragmentation that keep quality healthcare costly and out of reach for many.
 
In the past year, we have successfully acquired leading companies in minimally invasive surgery, neuro intervention, as well as, technology in the peripheral intervention space. The latest of which is Chocolate Touch, one of the most advanced drug-coated balloon technology for peripheral intervention use.

On the sales and distribution end, we now have access to over 4,000 hospitals and private clinics and are on track to covering 15,000 hospitals and clinics in 5 years. This is made possible by our growing sales and distribution acquisitions and investments, allowing us to leverage on them to directly access hospitals and clinics.  This super-efficient business model will bring medical innovations from R&D to practical applications in shorter lead time and cost, allowing us to fulfil our vision of making quality healthcare accessible to all.

We target to complete the first phase of construction in 2 years. By which, we will be able to develop and manufacture our products in neuro intervention, cardiac intervention, and tumour intervention therapy. Subsequently, additional capacity will be added to enable us to also independently develop and manufacture cost-effective and high-value medical consumables.

Beyond manufacturing, this facility will also serve as our base for direct collaborations with our global R&D teams.